B+
Bull case
0%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
SHC
Sotera HealthBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
0%
Probability
Target price
$19.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$15.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+67.5
Score
AI commentary
Earnings-related news tone is positive, but coverage is limited and social evidence is unavailable. The August 7 close was $18.86; the packet lacks a clean pre-release comparator and trusted attribution for the immediate market reaction. Post-print analyst revisions are unavailable. The deterministic prior remains negative over 20-120 days, so this is a monitoring-style follow-up rather than a high-conviction bullish signal.
RankAlpha Sentiment Codex - 2026-08-08
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06eventStrong Q2 with raised FY2026 outlookMedium impact
Sotera reported Q2 revenue growth of 9.2%, Adjusted EBITDA growth of 10.0%, Adjusted EPS growth of 30%, and raised full-year revenue and Adjusted EBITDA growth outlooks [#SEC-8K-2026-08-06].
2026-11-06catalystPost-print margin and growth digestionMedium impact
Nelson Labs delivered 5.4% constant-currency revenue growth, but six-month segment income declined 4.9% and higher costs pressured margins; Nordion growth also benefited partly from Cobalt-60 harvest timing [#SEC-8K-2026-08-06].
2027-08-08catalystExecution and deleveraging runwayHigh impact
Sustained pricing and volume execution at Sterigenics, strong Nordion growth, approximately $950 million of liquidity, 3.0x net leverage, and term-loan repricing savings could support a gradual rerating [#SEC-8K-2026-08-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology